Naptumomab estafenatox
- Generic Name
- Naptumomab estafenatox
- Drug Type
- Biotech
- CAS Number
- 676258-98-3
- Unique Ingredient Identifier
- 93T929W6LC
- Background
Naptumomab Estafenatox has been used in trials studying the treatment of Pancreatic Cancer, Renal Cell Carcinoma, and Non-Small-Cell Lung Carcinoma.
Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers
- Conditions
- Urothelial Carcinoma
- Interventions
- First Posted Date
- 2023-06-08
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Weill Medical College of Cornell University
- Registration Number
- NCT05894447
- Locations
- 🇺🇸
Weill Cornell Medicine/NewYork-Presbyterian Hospital, New York, New York, United States
ABR-217620 in Combination With Docetaxel in Patients With Advanced Non-small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2005-08-22
- Last Posted Date
- 2014-08-27
- Lead Sponsor
- Active Biotech AB
- Target Recruit Count
- 13
- Registration Number
- NCT00132379
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇩🇰Onkologisk Klinik, Rigshospitalet, Copenhagen, Denmark
🇷🇺City Multifield Hospital #2, City Center of Intensive Pulmonology and Thoracic Surgery, St. Petersburg, Russian Federation
ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer
- Conditions
- Non-Small-Cell Lung CarcinomaRenal Cell CarcinomaPancreatic Cancer
- Interventions
- First Posted Date
- 2003-03-18
- Last Posted Date
- 2014-08-27
- Lead Sponsor
- Active Biotech AB
- Target Recruit Count
- 44
- Registration Number
- NCT00056537
- Locations
- 🇳🇴
Det Norske Radiumhospitalet, Oslo, Norway
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇬🇧Paterson Institute for Cancer Research, Christie Hospital NHS Trust and Research Institute, Manchester, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.